Your session is about to expire
← Back to Search
Treatment (ICG lymphangiography) for Neck Dissection
N/A
Waitlist Available
Led By John Phay, MD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Healthy adult patients who are undergoing LEFT modified radical or selective (including zone IV) lymph node dissection for any indication; this includes patients who have had prior neck surgery
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights
Study Summary
This trial is testing a new way to see the thoracic duct during neck surgery, which may help prevent injury to it.
Eligible Conditions
- Neck Dissection
- Lymph Node Dissection
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Identify thoracic duct (TD) using indocyanine green (ICG)
Prevent injury to the TD
Recognize injury intra-operatively
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment (ICG lymphangiography)Experimental Treatment2 Interventions
Participants receive indocyanine green solution SC and undergo near-infrared imaging over 1-2 minutes during their standard of care neck surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lymphangiography
2018
N/A
~130
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,717 Previous Clinical Trials
40,953,266 Total Patients Enrolled
Ohio State University Comprehensive Cancer CenterLead Sponsor
323 Previous Clinical Trials
290,264 Total Patients Enrolled
John Phay, MDPrincipal InvestigatorOhio State University Comprehensive Cancer Center
Share this study with friends
Copy Link
Messenger